An image of multiple stacks of coins
Markets

AbbVie to Start Study on Alzheimer's Treatment

AbbVie Inc. ( ABBV ) announced on Jan. 25 the beginning of two studies to assess 8E12's efficacy and safety in people with early-onset Alzheimer's disease and PSP patients.

AbbVie's 8E12 is an antibody against the tau protein, which is under investigation in clinical studies.

The anti-tau are antibodies of recent discovery in mice. These antibodies against the tau proteins may severely reduce the accumulation of tau proteins through a special mechanism which prevents the absorption of the aggregates of tau proteins by the neuro cells.

The accumulation of tau proteins has been associated with the worsening of cognitive functions in degenerative diseases such as frontotemporal dementia and Alzheimer's disease.

In particular, the first of these two Phase 2 studies will evaluate the efficacy and the safety of 8E12 in 400 patients with early-onset Alzheimer's disease, and the second Phase 2 study will evaluate the efficacy and the safety of AbbVie's antibody against the tau protein, 8E12, in 180 PSP's adult patients.

The efficacy of AbbVie's 8E12 will be assessed in terms of delay in the progression of early-onset Alzheimer's disease and in terms of slow in the progression of progressive supranuclear palsy ( PSP ).

The early-onset Alzheimer's disease is a rare form of Alzheimer, which accounts for only 5% to 10% of all cases of Alzheimer.

The progressive supranuclear palsy, or PSP, is a degenerative disease that involves the progressive deterioration and death of specific brain parts.

The company says that "in recognition of the lack of treatment options available to patients with PSP, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to ABBV-8E12" and together with the European Medicines Agency (EMA), they "also granted Orphan Drug Designations to ABBV-8E12 for PSP."

On Jan. 27, AbbVie closed at $60.00 per share, down $1.27 from the previous close with a PB ratio of 15.07 and a PS ratio of 3.86.

Yesterday, a volume of 14,151,233 shares were traded on the New York Stock Exchange versus an average volume of 8.46 million traded over the last three months.

The stock is up since the beginning of the new year and gained 2.50%.

Disclosure: I have no positions in AbbVie Inc.

Start a free seven-day trial of Premium Membership to GuruFocus.

Premium Members

This article first appeared on GuruFocus .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PSP ABBV

Other Topics

Stocks

Latest Markets Videos